No SAEs in dialysis study of Akebia's AKB-6548

Akebia Therapeutics Inc. (NASDAQ:AKBA) jumped $1.37 (15%) to $10.36 on Tuesday after publication of an abstract showing that AKB-6548 led to no serious adverse events or treatment discontinuations in a Phase II pharmacokinetic study to treat anemia secondary to chronic kidney disease (CKD) in dialysis-dependent patients. The abstract was published in the Journal of the American Society of Nephrology in advance of the Kidney Week conference that began Tuesday in Philadelphia.

PK data from the open-label study in 12 patients showed the hemodialysis procedure had minimal impact on the clearance of AKB-6548. The data will be presented in a poster session on Friday. ...